Clinical Trials Directory

Trials / Terminated

TerminatedNCT02262000

Phase II Image Guided Stereotactic Ablative Radiotherapy for Non-Small Cell Lung Cancer

A Phase II Clinical Trial of Image Guided Stereotactic Ablative Radiotherapy (SABR) for T2 and Microscopic T3 (PL3), N0,M0 Non-small Cell Lung Cancer (NSCLC)

Status
Terminated
Phase
N/A
Study type
Interventional
Enrollment
3 (actual)
Sponsor
West Virginia University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This study will help researchers learn about the best dose of radiation to be used when treating large early stage non-small cell lung cancer (NSCLC) with a treatment called stereotactic ablative radiotherapy (SABR). Current treatments with SABR for early stage NSCLC show positive response. But, for large early stage NSCLC it may be better to give different SABR doses than what is used in routine early stage NSCLC treatment. It is not understood which dose is best for treating large early stage NSCLC. Therefore, this study can help researchers learn if giving a higher dose using SABR over a period of 5-10 treatment days can increase the chance of cure for large early stage NSCLC.

Detailed description

Treatment Plan: 7.5 Gy x 10 daily fractions delivered with volumetric modulated arc therapy (VMAT) or regular intensity-modulated radiation therapy (IMRT). * Optional schedule of 12 Gy x 5 daily fractions can may also be used ONLY in situations where dose constraints for organs at risk can be EASILY met while optimal planning target volume (PTV) coverage is achieved; but the 7.5 Gy x 10 daily fractions schedule is preferred. * All doses are prescribed to the tumor periphery. For this protocol, patients will be followed only up to 2 years post radiation therapy.

Conditions

Interventions

TypeNameDescription
RADIATIONImage Guided Stereotactic Ablative Radiotherapy

Timeline

Start date
2013-09-01
Primary completion
2016-07-07
Completion
2017-07-10
First posted
2014-10-10
Last updated
2021-01-22
Results posted
2021-01-22

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02262000. Inclusion in this directory is not an endorsement.